Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evidence-based assessment of treatment options for children with IgA nephropathies
Autore:
Wyatt, RJ; Hogg, RJ;
Indirizzi:
Lebonheur Childrens Med Ctr, Crippled Childrens Fdn, Res Ctr, Memphis, TN 38103 USA Lebonheur Childrens Med Ctr Memphis TN USA 38103 r, Memphis, TN 38103 USA Univ Tennessee, Hlth Sci Ctr, Ctr Hlth Policy, Memphis, TN 38103 USA Univ Tennessee Memphis TN USA 38103 tr Hlth Policy, Memphis, TN 38103 USA Med City Dallas Hosp, N Texas Hosp Children, Div Pediat Nephrol, Dallas, TX USA Med City Dallas Hosp Dallas TX USA n, Div Pediat Nephrol, Dallas, TX USA
Titolo Testata:
PEDIATRIC NEPHROLOGY
fascicolo: 2, volume: 16, anno: 2001,
pagine: 156 - 167
SICI:
0931-041X(200102)16:2<156:EAOTOF>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
HENOCH-SCHONLEIN NEPHRITIS; METHYLPREDNISOLONE PULSE THERAPY; ALTERNATE-DAY PREDNISONE; LONG-TERM PROGNOSIS; NEPHROTIC SYNDROME; CONTROLLED TRIAL; FISH-OIL; CORTICOSTEROID-THERAPY; PURPURA NEPHRITIS; BERGERS DISEASE;
Keywords:
IgA nephropathy; evidence-based assessment; Henoch-Schonlein purpura nephritis;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
78
Recensione:
Indirizzi per estratti:
Indirizzo: Wyatt, RJ Lebonheur Childrens Med Ctr, Crippled Childrens Fdn, Res Ctr, 50N Dunlap,Memphis, TN 38103 USA Lebonheur Childrens Med Ctr 50 N Dunlap Memphis TN USA 38103 USA
Citazione:
R.J. Wyatt e R.J. Hogg, "Evidence-based assessment of treatment options for children with IgA nephropathies", PED NEPHROL, 16(2), 2001, pp. 156-167

Abstract

We present an evidence-based evaluation of published data on therapy for children with various presentations of the IgA nephropathies - idiopathic IEA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis (HSPN). Particular attention has been paid to the outcome markers used in the studies reviewed, with the best evidence provided by markers highly associated with progressive renal failure. No treatment modality for either IgAN or HSPN in pediatric patients has been shown to be effective by a properly designed and administered randomized controlled trial (i.e., the highest level of evidence - level 1). Lower levels of evidence support the use of a variety of corticosteroid regimens, often in combination with other agents, although there are some conflicting studies in this area. No convincing evidence has been published to date to support the use of fish oil, angiotensin-converting enzyme inhibitors or tonsillectomy for the treatment of children with IgAN or HSPN. Well designed randomized controlled trials in children with the IgA nephropathies need to be undertaken.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 15:36:23